Abstract
British Journal of DermatologyVolume 186, Issue 6 p. e264-e264 Plain Language SummaryFree Access New insight into how mogamulizumab treatment benefits patients with Sézary syndrome First published: 03 June 2022 https://doi.org/10.1111/bjd.21305AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Linked Article: Roelens et al. Br J Dermatol 2022; 186:1010–1025 . Sézary syndrome (SS) is a rare form of skin cancer (T-cell lymphoma) arising in the skin from white blood cells. Management involves many successive treatments, as disease relapse and lack of response to treatment often occur. Also, patients with SS experience immunodeficiency as their disease progresses, this means their immune system is less able, or completely unable, to fight infectious diseases and cancer. Mogamulizumab therapy has been shown to increase progression-free survival in patients with SS. It is a monoclonal antibody treatment. This study from France included 26 patients with hard-to-treat SS that had not responded to at least one systemic treatment (given by mouth or injection). The authors wanted to find out more about how mogamulizumab might improve patients’ long-term clinical response. They undertook various investigations including using a process called multicolour flow cytometry. Both malignant and non-malignant T-cells were monitored. They found that mogamulizumab not only eradicates malignant cells but also potentially contributes to the restoration of efficient immunity. In conclusion, this study provides new insights that will help with the management of this condition. Volume186, Issue6June 2022Pages e264-e264 RelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
